Agnieszka Orzińska1, Katarzyna Guz1, Michał Mikula2, Maria Kulecka3, Anna Kluska2, Aneta Balabas2, Monika Pelc-Kłopotowska1, Jerzy Ostrowski2,3, Ewa Brojer1. 1. Department of Immunohaematology and Immunology of Transfusion Medicine, Institute of Haematology and Blood Transfusion, Warsaw, Poland. 2. Department of Genetics, "Maria Sklodowska-Curie" Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland. 3. Medical Centre of Postgraduate Education, Department of Gastroenterology, Hepatology and Clinical Oncology, Warsaw, Poland.
Abstract
BACKGROUND: Matching the compatibility of donor blood with the recipient's antigens prevents alloimmunisation. Next-generation sequencing (NGS) technology is a promising method for extensive blood group and platelet antigen genotyping of blood donors. It circumvents the limitations of detecting known alleles based on predefined polymorphisms and enables targeted sequencing on a massive scale. The aim of this study was to evaluate the NGS AmpliSeq application on the Ion Torrent platform as a screening tool for genotyping blood donors' erythrocyte/platelet antigens. MATERIALS AND METHODS: Primers for regions encoding antigens RhD (exons 5, 7), Rhc, RhE/e, Fya/b, Jka/b, M/N, S/s, HPA-1, 2, 3, 5, 15 were designed with Ion AmpliSeq Designer with manual inclusion of RHCE*C primers. DNA libraries of 57 regular blood donors with determined phenotype/genotype (prepared using the Ion AmpliSeq Library Kit and 14 primer pairs) were sequenced on the Ion Torrent PGM using 316v2 chips and 200 bp chemistry. RESULTS: Sequencing was successful in all but the MN and HPA-5 regions. Mean sequencing coverage in one experiment was 4,606 reads, except for the RHCE*C region (mean 568 reads). NGS results agreed with the known phenotype/genotype of donors except in one phenotypically Fy(a+b-) case in whom FY*A/FY*B alleles were found. Reading rates for homozygotes were 97-100%, while they were around 50% for heterozygotes. NGS of RHD regions led to identification of mutations in two RhD negative donors. DISCUSSION: NGS can be performed as a screening test to determine erythrocyte/platelet antigens in blood donors. This method allowed testing of 48 donors for 14 features (200 bp long) with the depth of a few thousand reads simultaneously, and the estimation of natural chimerism or hemi/homozygotic status. NGS screening can be adjusted to the genetic background of a given tested population.
BACKGROUND: Matching the compatibility of donor blood with the recipient's antigens prevents alloimmunisation. Next-generation sequencing (NGS) technology is a promising method for extensive blood group and platelet antigen genotyping of blood donors. It circumvents the limitations of detecting known alleles based on predefined polymorphisms and enables targeted sequencing on a massive scale. The aim of this study was to evaluate the NGS AmpliSeq application on the Ion Torrent platform as a screening tool for genotyping blood donors' erythrocyte/platelet antigens. MATERIALS AND METHODS: Primers for regions encoding antigens RhD (exons 5, 7), Rhc, RhE/e, Fya/b, Jka/b, M/N, S/s, HPA-1, 2, 3, 5, 15 were designed with Ion AmpliSeq Designer with manual inclusion of RHCE*C primers. DNA libraries of 57 regular blood donors with determined phenotype/genotype (prepared using the Ion AmpliSeq Library Kit and 14 primer pairs) were sequenced on the Ion Torrent PGM using 316v2 chips and 200 bp chemistry. RESULTS: Sequencing was successful in all but the MN and HPA-5 regions. Mean sequencing coverage in one experiment was 4,606 reads, except for the RHCE*C region (mean 568 reads). NGS results agreed with the known phenotype/genotype of donors except in one phenotypically Fy(a+b-) case in whom FY*A/FY*B alleles were found. Reading rates for homozygotes were 97-100%, while they were around 50% for heterozygotes. NGS of RHD regions led to identification of mutations in two RhD negative donors. DISCUSSION: NGS can be performed as a screening test to determine erythrocyte/platelet antigens in blood donors. This method allowed testing of 48 donors for 14 features (200 bp long) with the depth of a few thousand reads simultaneously, and the estimation of natural chimerism or hemi/homozygotic status. NGS screening can be adjusted to the genetic background of a given tested population.
Authors: S Stabentheiner; M Danzer; N Niklas; S Atzmüller; J Pröll; C Hackl; H Polin; K Hofer; C Gabriel Journal: Vox Sang Date: 2010-12-07 Impact factor: 2.144
Authors: Stephanie A Boccoz; Gaelle C Le Goff; Celine A Mandon; Benjamin P Corgier; Loïc J Blum; Christophe A Marquette Journal: J Mol Diagn Date: 2015-11-29 Impact factor: 5.568
Authors: Michael A Quail; Miriam Smith; Paul Coupland; Thomas D Otto; Simon R Harris; Thomas R Connor; Anna Bertoni; Harold P Swerdlow; Yong Gu Journal: BMC Genomics Date: 2012-07-24 Impact factor: 3.969
Authors: Celina Montemayor-Garcia; Panagiota Karagianni; David A Stiles; Erika M Reese; Danielle A Smellie; Debrean A Loy; Kimberly Y Levy; Magdalene Nwokocha; Marina U Bueno; Jeffery L Miller; Harvey G Klein Journal: Transfusion Date: 2018-10-12 Impact factor: 3.157
Authors: William J Lane; Connie M Westhoff; Nicholas S Gleadall; Maria Aguad; Robin Smeland-Wagman; Sunitha Vege; Daimon P Simmons; Helen H Mah; Matthew S Lebo; Klaudia Walter; Nicole Soranzo; Emanuele Di Angelantonio; John Danesh; David J Roberts; Nick A Watkins; Willem H Ouwehand; Adam S Butterworth; Richard M Kaufman; Heidi L Rehm; Leslie E Silberstein; Robert C Green Journal: Lancet Haematol Date: 2018-05-17 Impact factor: 18.959
Authors: Stephanie Maria Vorholt; Nele Hamker; Hagen Sparka; Jürgen Enczmann; Thomas Zeiler; Tanja Reimer; Johannes Fischer; Vera Balz Journal: Transfus Med Hemother Date: 2020-01-08 Impact factor: 3.747